Entero Therapeutics, Inc. Common Stock
Symbol: ENTO (NASDAQ)
Company Description:
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
- Today's Open: $0
- Today's High: $0
- Today's Low: $0
- Today's Volume: 0
- Yesterday Close: $4.06
- Yesterday High: $4.3718
- Yesterday Low: $3.89
- Yesterday Volume: 141.32K
- Last Min Volume: 0
- Last Min High: $0
- Last Min Low: $0
- Last Min VWAP: $0
- Name: Entero Therapeutics, Inc. Common Stock
- Website: https://www.enterothera.com
- Listed Date: 2016-10-11
- Location: BOCA RATON, FL
- Market Status: Active
- CIK Number: 0001604191
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $9.21M
- Round Lot: 100
- Outstanding Shares: 2.12M
- Asset Type: CS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-06 | 8-K | View |
| 2025-09-26 | SEC STAFF ACTION | View |
| 2025-09-17 | 424B3 | View |
| 2025-09-15 | EFFECT | View |
| 2025-09-12 | 8-K | View |
| 2025-09-10 | S-1/A | View |
| 2025-09-09 | 8-K | View |
| 2025-08-26 | S-1 | View |
| 2025-08-26 | PRE 14A | View |
| 2025-08-18 | 3 | View |
| 2025-08-18 | 3 | View |
| 2025-08-18 | D | View |
| 2025-08-15 | 8-K | View |
| 2025-08-14 | 10-Q | View |
| 2025-08-11 | 8-K | View |
| 2025-07-16 | 8-K | View |
| 2025-07-08 | 8-K | View |
| 2025-07-02 | S-1/A | View |
| 2025-07-02 | 8-K | View |
| 2025-06-30 | 8-K | View |
